[The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Cha
Jae Myung
JM
Kim
Hyo Jong
HJ
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000209:etiology; D007970:Leukopenia / Q000139:chemically induced; D015122:Mercaptopurine / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D015122:Mercaptopurine; D001379:Azathioprine